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Abstract
 
Formation of the atherosclerotic intima must involve al-
tered metabolism of the elastin-rich arterial extracellular
matrix. Proteases potentially involved in these processes re-
main unclear. This study examined the expression of the po-
tent elastases cathepsins S and K in human atheroma. Nor-
mal arteries contained little or no cathepsin K or S. In
contrast, macrophages in atheroma contained abundant im-
munoreactive cathepsins K and S. Intimal smooth muscle
cells (SMC), especially cells appearing to traverse the inter-
nal elastic laminae, also contained these enzymes. Extracts
of atheromatous tissues had approximately twofold greater
elastase-specific activity than extracts of uninvolved arter-
ies, mostly due to cysteine proteases. Cultured human SMC
displayed no immunoreactive cathepsins K and S and ex-
hibited little or no elastolytic activity when incubated with
insoluble elastin. SMC stimulated with the atheroma-associ-
ated cytokines IL-1
 
b
 
 or IFN-
 
g
 
 secreted active cathepsin S
and degraded substantial insoluble elastin (15–20 
 
m
 
g/10
 
6
 
cells/24 h). A selective inhibitor of cathepsin S blocked 
 
.
 
 80%
of this elastolytic activity. The presence of cathepsins K and
S at sites of vascular matrix remodeling and the ability of
SMC and macrophages to use these enzymes to degrade
elastin supports a role for elastolytic cathepsins in vessel
wall remodeling and identifies novel therapeutic targets in
regulating plaque stability. (
 
J. Clin. Invest.
 
 1998. 102:576–
 
583.) Key words: atherosclerosis
 
 
 
• 
 
cysteine protease 
 
•
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• 
 
elastolytic activity
 
Introduction
 
Remodeling of the extracellular matrix of blood vessels, and in
particular, the degradation of elastin, contributes importantly
to numerous aspects of formation and complication of athero-
sclerotic lesions. Early in formation of the thickened intima,
smooth muscle cells (SMC)
 
1
 
 that may migrate from the tunica
media into the developing intima must penetrate the internal
elastic lamina. The compensatory enlargement characteristic
of the evolving atherosclerotic lesion must likewise involve re-
modeling of constituents of the arterial extracellular matrix,
including elastin. Recent clinical and pathological evidence
suggests that inflammatory cells, especially macrophages, ac-
cumulate in regions of plaques most susceptible to dissolution
and rupture (1–3). The mechanisms of degradation of the arte-
rial extracellular matrix in these various contexts remain un-
clear. Substantial evidence supports the involvement of matrix
metalloproteinases (MMP) in this process (4–6). Some studies
have also implicated serine proteases in vascular remodeling
(7, 8). Cysteine proteases have received much less consider-
ation in this regard, even though macrophages and SMC with
greatly expanded lysosomal compartments figure prominently
in the histopathology of atherosclerotic plaques.
Cysteine proteases have several properties that suggest
that they might contribute to arterial remodeling during
atherogenesis, if they were expressed in these lesions. Several
cysteine endoproteases, i.e., cathepsins K, L, and S, have po-
tent elastolytic activity (9–12). Cathepsin K is the most potent
mammalian elastase yet described (13, 14), and also possesses
collagenolytic activity (15). Although all members of this en-
zyme family have acidic pH optima, cathepsin S is stable at
neutral pH, where it retains nearly as much elastase activity as
leukocyte elastase (10, 11, 16, 17). Although these enzymes are
thought to generally reside in and function optimally within
acidic lysosomes, recent evidence indicates that these elastases
may also function extracellularly at or near the cell surface.
Monocyte-derived human macrophages become markedly
elastolytic during in vitro culture and predominantly use cys-
teine proteases to degrade extracellular elastin (12). Acquisi-
tion of a degradative phenotype correlates with the ability of
the macrophages to contact elastin, create an acidic pericellu-
lar space, and secrete elastolytic cysteine proteases, especially
cathepsins S and L, into the contact zone (12, 18). This degra-
dative mechanism is reminiscent of the bone macrophage, os-
teoclasts. Indeed, in osteoclasts, cathepsin K appears to be the
major protease involved in extracellular matrix metabolism
necessary for normal bone growth and remodeling (13). Defi-
ciency of this enzyme results in accumulation of bone matrix
mostly around rather than in osteoclasts, consistent with the
primary site of action of cathepsin K in the pericellular space
(19). Together, these studies establish that under certain con-
ditions macrophages utilize the elastolytic cathepsins to re-
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model extracellular matrix, although cathepsin K protein has
only been observed in bone, one study generally demonstrated
cathepsin K mRNA and protein expression in human breast
carcinoma (20).
Atherosclerotic plaques contain abundant macrophages.
These cells accumulate at sites of weakening of the extracellu-
lar matrix, which predispose to plaque rupture. Disruption of
atherosclerotic plaques frequently causes thrombosis and pre-
cipitates the acute manifestations of atherosclerosis, including
unstable angina and acute myocardial infarction (2, 3). In view
of the proteolytic potential of cathepsins K and S, and their
possible presence in the very cell types found at sites of plaque
liability, we investigated the expression of these proteases in
normal and atherosclerotic human arteries and their regula-
tion and function in vitro in cultured vascular SMC.
 
Methods
 
Human tissue.
 
Atherosclerotic plaques from human coronary (
 
n
 
 
 
5
 
 9)
and carotid (
 
n
 
 
 
5
 
 15) arteries and nonatherosclerotic arteries (
 
n
 
 
 
5
 
 12)
were obtained from transplantation donors, at endarterectomy, and
at autopsy. Immunohistochemical localization of cathepsin S or K did
not depend on whether frozen or paraffin sections were studied.
 
Immunocytochemistry.
 
Serial cryostat sections after fixing in cold
acetone at 
 
2
 
20
 
8
 
C for 5 min or paraffin sections after deparaffiniza-
tion in xylene and rehydration in graded ethanols were stained using
the avidin-biotin-peroxidase method. The reaction was visualized
with 3-amino-9-ethyl carbazole as substrate (Sigma Chemical Co., St.
Louis, MO). Staining for cathepsin S required 10 min pretreatment
with 1 N HCl at room temperature before incubation with the pri-
mary antibodies. Sections were counterstained with Gill’s hematoxy-
lin solution.
Cell types were identified using monoclonal anti–muscle actin
HHF-35 (Enzo Diagnostics, Syosset, NY); monoclonal anti–human
macrophage HAM-56, and CD-68, monoclonal anti–human leuko-
cyte common antigen (DAKO Corporation, Carpinteria, CA). Rab-
bit polyclonal antibodies against human cathepsins S and K were pro-
duced as described previously (21, 22), and affinity purified using
immobilized antigen. To control for antibody specificity, immunohis-
tochemical studies were performed in parallel with a preparation of
antibody that had been incubated overnight at 4
 
8
 
C with a 20-fold ex-
cess of antigen.
 
Cell culture.
 
SMC obtained from human saphenous veins were
subcultured at passages 2–5 into four- or eight-chamber slides (Lab-
Tek, Naperville, IL) for immunostaining or into 150-cm
 
2
 
 flasks
(Corning, Inc., Corning, NY). SMC were grown to confluency in
DME (Bio Whittaker, Walkersville, MD) containing 100 U/ml penicil-
lin B, 100 
 
m
 
g/ml streptomycin, and 1.25 
 
m
 
g/ml amphotericin and sup-
plemented with 10% FCS. Cells were stimulated for 24 h with re-
combinant IL-1
 
b
 
 (10 ng/ml; Genzyme Corp., Cambridge, MA),
recombinant human TNF-
 
a
 
 (10 ng/ml; Genzyme Corp.), or human re-
combinant IFN-
 
g
 
 (400 U/ml; Becton Dickinson Labware, Bedford,
MA). Stock solutions of these cytokines contained 0.1% pyrogen-free
human serum albumin as a carrier.
 
Western blot analysis.
 
Frozen tissues from four nonatheroscle-
rotic arteries and five carotid plaques were pulverized and lysed (0.3 
 
m
 
g
tissue per milliliter of lysis buffer) as described below. After 1 h incu-
bation at 37
 
8
 
C, the lysates were clarified by centrifuging at 16,000 
 
g
 
for 15 min. The protein concentration for each lysate was determined
using a protein assay system according to the manufacturer (Bio-Rad
Dc; Bio-Rad Laboratories, Hercules, CA). 300 
 
m
 
g of protein from
each sample were separated on 12% SDS-PAGE and blotted onto ni-
trocellulose filter (Schleicher and Schuell, Keene, NH). The filter was
then incubated with 5% nonfat milk/PBS overnight to block nonspe-
cific binding sites. Immunoblotting used immunopurified antibodies
against human cathepsins S or K (1:200 dilution) (19, 21). Blots were
developed using chemiluminescence (ECL system; New England Nu-
clear, Boston, MA).
 
Northern blot analyses.
 
Four nonatherosclerotic aortas and five
atherosclerotic carotid plaques were pulverized and total RNAs pre-
cipitated from a modified guanidium isothiocyanate lysate with iso-
propanol according to the manufacturer’s instructions (Stratagene
Inc., La Jolla, CA). Total RNAs were dissolved in diethylpyrocarbon-
ate-treated distilled water and 20 
 
m
 
g of total RNA from each sample
was separated on 1.2% agarose gels followed by electroblotting onto
membrane (Maximum Strength Nytran Plus; Schleicher and Schuell).
To analyze SMC RNA, 15,000,000 SMCs from each culture were lysed
in guanidinium isothiocyanate lysis buffer and the RNA was pre-
pared as described previously (22, 23). RNA blots were then pre-
hybridized and hybridized with 
 
a
 
-[
 
32
 
P]dCTP (New England Nuclear)
labeled cathepsins S and K full-length cDNA fragments, and glyceral-
dehyde-3-phosphate dehydrogenase cDNA fragment (Clontech, Palo
Alto, CA) respectively, in Express Hyb Solution (Clontech) for 1 h
followed by sequential 20 min of washing in 2
 
3
 
 SSC/2% SDS, 0.5
 
3
 
SSC/0.5% SDS, and 0.1
 
3
 
 SSC/0.1% SDS, respectively. Membranes
were then exposed to X-omat film (Eastman Kodak, Rochester, NY),
and the autoradiograms were quantified by densitometric analysis us-
ing National Institutes of Health Image software.
 
Elastase assays.
 
Tissue from five nonatherosclerotic aortas and
seven carotid plaques was snap-frozen in liquid nitrogen and stored at
 
2
 
80
 
8
 
C until study. Tissue samples were pulverized in a liquid nitro-
gen-cooled aluminum mortar and divided into two portions. One
half, 
 
z
 
 0.2 g of tissue, was lysed in 0.5 ml of buffer optimized for
acidic protease activity of cathepsins (11) containing 1% Triton X-100,
40 mM sodium acetate, and 1 mM EDTA, pH 5.5; and another half
was lysed in a buffer optimized for a study of neutral MMP activity
(5), 10 mM phosphate, pH 7.2, containing 150 mM Na chloride (PBS),
and 1% Triton X-100, 0.015 M CaCl
 
2
 
, 0.1% SDS, 0.5% Na deoxycho-
late, and 0.2% Na azide (PBSTS). SDS was included during assay to
optimize elastolytic activity (24). The tissue was extracted at 37
 
8
 
C for
1 h, and the lysates were then collected by centrifuging at 16,000 
 
g
 
 for
10 min. Tissue lysate elastolytic activity was assayed as described pre-
viously (11). Briefly, 50 
 
m
 
g total protein in 10 
 
m
 
l of 150 mM DTT, and
240 
 
m
 
l of lysate assay buffer containing 0.05% Triton X-100, 20 mM
sodium acetate, and 1 mM EDTA, pH 5.5, were added onto the 24-
well plate coated with 200 
 
m
 
g of [
 
3
 
H]elastin per well. The same
amount of total protein in PBSTS buffer, pH 7.2. All assays were per-
formed in duplicate. [
 
3
 
H]Elastin (bovine ligamentum nuchae; Elastin
Products, St. Louis, MO) was prepared as previously described (24).
The specific activity of the preparation was 700 cpm/
 
m
 
g. The plate was
incubated overnight at 37
 
8
 
C. Samples were then collected and spun at
16,000 
 
g
 
 for 15 min to separate soluble product from undegraded, in-
soluble elastin. The soluble radioactivity was measured by liquid-scin-
tillation spectroscopy. Parallel incubations with inhibitors were used
to distinguish the contribution to elastin degradation of cysteine pro-
teases (20 
 
m
 
M E64 [
 
trans
 
-epoxysuccinyl-
 
L
 
-leucylamido-{4-guanidino}
butane]) or MMPs (20 mM EDTA), respectively. All reagents were
purchased from Sigma Chemical Co., unless stated otherwise.
SMC were assayed for elastase activity in cocultures with insolu-
ble [
 
3
 
H]elastin. SMCs obtained from saphenous veins were seeded on
24-well plate (Becton Dickinson, Lincoln Park, NJ) at 1 
 
3
 
 10
 
5
 
 cells
per well in 1 ml of DME/10% FCS. After stimulating the cells with
500 U/ml IFN-
 
g
 
 or 10 ng/ml IL-1
 
b
 
 for 24 h, 200 
 
m
 
g of [
 
3
 
H]elastin
(1300 cpm/
 
m
 
g) was added into each well in the absence and presence
of protease inhibitors including E64d (20 
 
m
 
M; Sigma Chemical Co.),
LHVS (morpholinurea-leucine-homophenylalanine-vinylsulfone-phe-
nyl, 5 nM; Arris Pharmaceutical, Inc., South San Francisco, CA),
TIMP-1 (100 ng/ml; Oncogene, Cambridge, MA), and PMSF (1 mM;
Sigma Chemical Co.). Cells without IFN-
 
g
 
 stimulation were treated
in the same way as stimulated cells. After further incubation at 37
 
8
 
C
for 4 d, media were collected and centrifuged at 16,000 
 
g
 
 for 15 min-
utes. Supernatant (200 
 
m
 
l) was carefully transferred into 5 ml of aqua-
sol-2 for scintillation counting of digested [
 
3
 
H]elastin. Each treatment
was performed in four separate wells and each well was counted in 
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duplicate. Results were presented as mean
 
6
 
SD of three separate ex-
periments.
 
Elaboration of active cathepsin S by cultured SMC.
 
Human saphe-
nous vein SMC were cultured in serum-free medium (25) for one day
before stimulation with IFN-
 
g
 
 as described above. Stimulation was
carried on continuously for 4 d in the presence of [
 
125
 
I]tyrosine-
alanine-diazomethylketone ([
 
125
 
I]tyr-ala-CHN
 
2
 
), which irreversibly
binds and inhibits active cysteine proteases (12). This probe should
label both intracellular and extracellular active cysteine proteases.
The culture medium was then collected and concentrated by precipi-
tation with TCA (5%) in the presence of 0.3% bovine calf serum.
Samples were neutralized and both the protein pellets and cells solu-
bilized in Laemmli sample buffer and immunoblotted for cathepsin S
as described above. The blot was then exposed to X-Omat film (East-
man Kodak) to visualize [
 
125
 
I]tyr-ala-CHN
 
2
 
-labeled cysteine pro-
teases. As control, released lactate dehydrogenase activity in the
medium was monitored spectrophotometrically according to the
manufacturer’s instructions (Sigma Diagnostics). Immunoblots were
also reprobed with antibodies to an additional cytoplasmic enzyme
marker, mitogen-activated kinase (New England Biolabs, Boston,
MA) to assess nonspecific release of intracellular contents during the
cultures.
 
Results
 
Foam cells in human atheroma contain immunodetectable
cathepsins S and K.
 
In nonatherosclerotic human arteries (
 
n
 
 
 
5
 
12), immunohistochemical evaluation showed negligible ex-
pression of cathepsins S or K protein (Fig. 1, 
 
top
 
). In athero-
matous carotid or coronary arteries (
 
n
 
 
 
5
 
 24), we observed
different patterns of expression of these cathepsins depending
on the morphology of the particular lesion in less fibrous, non-
occlusive lesions (
 
n
 
 
 
5
 
 7) immunoreactive cathepsins S and K
tended to localize not only in regions of the expanding intima
but also in the subjacent medial smooth muscle cells (Fig. 1,
 
middle
 
). In contrast, medial SMC in the normal arteries (
 
n
 
 
 
5
 
9) consistently lacked cathepsin S and K expression (compare
Fig. 1, 
 
top
 
 to Fig. 1, 
 
middle
 
). In advanced fibrous plaques (
 
n
 
 
 
5
 
17) (Fig. 1, 
 
bottom
 
), cathepsins K and S localized in the intima
both in the fibrous cap and in regions of foam cell accumula-
tion, in the shoulders of lesions more prominently than in the
lipid-rich core. Interestingly, in the more advanced plaques,
the underlying medial SMC appeared to express less cathepsin
S than they did in less fibrous, raised lesions, which likely rep-
resent an earlier stage in lesion evolution. Both snap-frozen
and paraffin-embedded tissue yielded similar findings.
We found cathepsin K-positive SMC-derived foam cells in
the fibrous cap of atheromata (Fig. 2, 
 
top left
 
), and in the mac-
rophage-derived foam cells in the shoulder area of these le-
sions (Fig. 2, 
 
bottom left
 
 and 
 
right
 
). The lack of reaction with
an antibody pre-absorbed with an excess of recombinant
cathepsin K established the specificity of staining under the
conditions used in these experiments (Fig. 2, 
 
top right
 
). In all
atherosclerotic plaques examined (
 
n
 
 
 
5
 
 24), macrophages always
contained immunodetectable cathepsins S and K regardless of
the plaque morphology, or the abundance of macrophages.
Two-color immunohistochemical analysis substantiated the lo-
calization of cathepsin S and cathepsin K in both smooth mus-
cle cells and macrophages (data not shown).
At the earlier stages of atherogenesis, such as diffuse inti-
mal thickening (
 
n
 
 
 
5
 
 3) and fatty streaks (
 
n
 
 
 
5
 
 4), we frequently
observed areas with interruption and fragmentation of the in-
ternal elastic lamina (Fig. 3, 
 
middle
 
). Interestingly, medial
SMC appearing to migrate into the intima contained both
cathepsins tested (illustrated here by staining for cathepsin K,
Fig. 3, 
 
bottom
 
).
 
Expression of cathepsins S and K protein and mRNA in
atheroma vs. normal arterial tissue.
 
Immunoreactive cathep-
sin K protein colocalizes with cathepsin S within atheroma
(Figs. 1–3). Extracts of atheroma (
 
n
 
 
 
5
 
 5) and normal arteries
(
 
n
 
 
 
5
 
 4) were analyzed by Western and Northern blotting. Im-
munoblotting (Fig. 4 
 
A
 
) confirmed increased cathepsin S and
K proteins in atheroma. The apparent sizes of the proteins
were 28 and 29 kD, respectively, consistent with the reported
sizes of the active forms of these cathepsins (11, 22). Densito-
metric analysis of Northern blotting (Fig. 4 
 
B
 
) showed a three-
to fourfold increase in cathepsin S mRNA in extracts of ather-
oma. Interestingly, similar levels of cathepsin K mRNA were
found in both atherosclerotic and normal tissues.
 
Atheroma extracts have elevated elastase activity.
 
To test
whether the cathepsins S and K expressed by foam cells in
atheroma can actually degrade an extracellular matrix compo-
nent, we tested the elastolytic activity of tissue extracts from
nonatherosclerotic arteries (
 
n
 
 
 
5
 
 5) and atherosclerotic plaques
(
 
n
 
 
 
5
 
 7). When assayed under conditions that optimize cysteine
protease activity, plaque extracts showed almost twofold
higher acidic, SH-dependent elastolytic activity than those
Figure 1. Cathepsin S (left) and cathepsin K (right) distribution in 
normal and atheromatous arteries, disclosed by the red–brown stain-
ing due to the aminoethyl carbazole reaction product. A nonathero-
sclerotic artery (top) contains few if any cathepsin S- or K-positive 
cells. Fatty streaks (middle) have cathepsin S- and K-positive cells in 
the expanded intima as well as in medial SMC. In more advanced fi-
brous plaques (bottom), cathepsin-containing cells localized in the fi-
brous cap, the SMC of the tunica media show weak or no staining. 
These results are representative of findings in 12 nonatherosclerotic 
arteries and 24 atherosclerotic lesions studied. Arrows, internal elas-
tic lamina. (Bars, 200 mm).Regional Expression of Elastolytic Cathepsins S and K in Human Atheroma 579
from nonatheromatous arterial tissues (Fig. 5). Approximately
40% of the elastolytic activity from tissue extracts of athero-
sclerotic plaques was inhibited by the cysteine protease inhibi-
tor E64. In contrast, when assayed under conditions that opti-
mize MMP activity, neutral, metal-dependent elastolysis of the
radioactive substrate was much lower and showed no signifi-
cant difference for extracts from atherosclerotic vs. uninvolved
tissue. Approximately 50% of the activity in the lysates was
due to neither cysteine proteases nor metalloproteases, and
this activity did not differ between atherosclerotic and normal
tissues (Fig. 5). The basis for this activity remains undefined.
SMC express cathepsins K and S protein and mRNA. Pre-
vious studies have established the capacity of macrophage/os-
teoclasts to express cathepsins S and K (11, 14, 19). The in situ
findings reported above suggested that SMC might also syn-
thesize these enzymes within human atheroma. Alternatively,
the immunoreactive cathepsins associated with arterial SMC in
the diseased arteries may have bound to smooth muscle cells
after elaboration by neighboring macrophages, a cell type
known to express these enzymes. We therefore tested the ca-
pacity of cultured SMC, free of mononuclear phagocytes, to
express these cathepsins.
Under usual culture conditions, human vascular SMC dis-
play no immunoreactive cathepsin S (Fig. 6, top). However, af-
ter exposure to IL-1b (10 ng/ml, 24 h) the cultured SMC uni-
formly contain immunoreactive cathepsin S (Fig. 6, middle).
We obtained similar results with TNF-a (10 ng/ml, 24-h expo-
sure) and IFN-g (400 U/ml, 24 h) (data not shown). The IL-1b-
stimulated SMC cultures showed no staining with anti–cathep-
sin S antibodies, which were preabsorbed with recombinant
protein (Fig. 6, bottom). In contrast, we found very low and
similar levels of immunoreactive cathepsin K expression in
VSMC with or without IL-1b stimulation (data not shown).
Thus, under these culture conditions, cytokine-stimulated
SMC predominantly express cathepsin S.
To characterize more completely the ability of cytokines
implicated in atherogenesis to regulate the cathepsin S gene
expression in SMC, we performed Northern blot analyses of
total RNA from human vascular SMC cultured under the same
conditions. We found that treatment with IFN-g (400 U/ml,
24 h), and IL-1b (10 ng/ml, 24 h) increased the expression of
cathepsin S mRNA . 6-, and 3.3-fold, respectively, as deter-
mined by densitometric analysis, while unstimulated SMC ex-
pressed very low levels of this mRNA (Fig. 7). Cathepsin K
mRNA showed similar levels of expression under basal condi-
tions, and after cytokine stimulation (Fig. 7). In the context of
cytokines as a potential stimulus for cathepsin S mRNA and
protein expression, we colocalized immunoreactive IL-1b and
cathepsin S in areas rich in macrophage-derived foam cells
within the shoulder region of atherosclerotic plaques (data not
shown).
Figure 2. Cathepsin K expression in human atheroma (generated by 
using an affinity-purified rabbit anti–human cathepsin K antibody). 
SMC in the fibrous cap (top left) contain cathepsin K protein. In all 
atherosclerotic plaques examined, macrophages in the shoulder area 
contain immunodetectable cathepsin K (bottom). The lack of reac-
tion with an antibody pre-absorbed with an excess of recombinant 
cathepsin K established the specificity of antibodies used under these 
conditions (top right).
Figure 3. Colocalization of cathepsin K-positive SMC with areas of 
internal elastic lamina fragmentation and medial SMC migration. 
Medial SMC and those that appear to migrate into the intima in fatty 
streaks (top, staining for a-actin, n 5 4) colocalize with fragmentation 
of the internal elastic lamina (middle, Verhoff–van Gieson staining), 
and express cathepsin K (bottom) 3400.580 Sukhova et al.
IFN-g-stimulated vascular SMC degrade elastin. To test the
function of cysteine elastases in SMC, we assayed the ability of
the intact cells to degrade elastin. Cultured SMC exhibit little
or no elastolytic activity under basal conditions (Fig. 8 A). Ex-
posure to IFN-g (400 U/ml for 24 h) substantially augmented
elastin degradation by SMC cultures over the ensuing 4 d. The
comparison of Figs. 7 and 8 shows a direct correlation between
the induction of cathepsin S expression and elastolytic activity
of cultured SMC. Further, a selective cathepsin S and K inhibi-
tor, LHVS, as well as an inhibitor of all papain-like proteases,
E64, reduced elastolytic activity . 80%. TIMP-1 and PMSF re-
duced elastin degradation to a much lesser extent (Fig. 8 A).
Cultured SMC stimulated by IL-1b (10 ng/ml) also showed el-
evated elastolytic activity as compared with nonstimulated
control (8.760.2 vs. 3.960.5 mg of elastin/106 cells/24 h). About
75% of this activity was inhibited by E64, and , 30% was in-
hibited by TIMP-1 or PMSF.
Elastin degradation by intact SMC could be due to either
extracellular release of active cathepsin S or internalization of
small amounts of elastin followed by intracellular degradation.
To determine whether cytokine-stimulated SMC secrete an ac-
tive form of cathepsin S, supernatants of control and cytokine-
stimulated cells were concentrated and analyzed for cathepsin
S by immunoblotting. No detectable cathepsin S was released
by unstimulated SMC, whereas the 4-d supernatant of IFN-g–
stimulated SMC did contain the 28-kD active form of cathep-
sin S (Fig. 8 B). That the released cathepsin S was active was
verified by its binding [125I]tyr-ala-CHN2, an active-site inhibi-
tor of papain-type cysteine proteases (Fig. 8 B). Because this
inhibitor penetrates cells and could be incorporated into cathep-
sin S intracellularly, we cannot be sure whether cathepsin S is
secreted in an active form or activated from its proform after
release. Notably, lysates of SMC contained more cathepsin B
than S, as judged by active-site labeling, whereas supernatants
contained much more cathepsin S (Fig. 8 B), suggesting secre-
tion rather than cell death as a source of released enzyme. This
interpretation was supported by assays of released lactate de-
hydrogenase, which showed no increase during the 4 d of cul-
ture, as well as by the absence of immunoreactive mitogen-
activated kinase, a cytoplasmic protein expressed in SMC, in
the culture supernatants (data not shown). Thus, while we can-
not exclude the possibility that elastin degradation by cyto-
kine-stimulated SMC is in part due to internalization of elas-
tin, our data show that stimulated SMC capable of mediating
considerable elastin degradation can secrete active cathepsin S.
Figure 4. (A) Western blot analysis of protein extracts from both hu-
man normal and atherosclerotic arteries. An equal amount of protein 
for each sample was loaded and immunoblotted using rabbit antibod-
ies against human cathepsins S and K (1:200 dilution). Both a 28-kD 
cathepsin S band and a 29-kD cathepsin K band, consistent with the 
sizes of the active enzymes, were visualized. (B) Northern blot analy-
sis of human cathepsins S and K in normal arteries and atheromas. 
20 mg of total RNA were used for each sample and the blot was 
probed sequentially with labeled cathepsin S and K cDNAs and then 
with glyceraldehyde-3-phosphate dehydrogenase (G3PDH) cDNA 
as a control for RNA loading.
Figure 5. Effect of selective inhibitors on cathepsin and metal-depen-
dent elastolytic activity of tissue extracts from human atheroma vs. 
nonatherosclerotic arteries (non-athero). Elastase activity was deter-
mined as described in Methods. Tissue extracts without inhibitors (2) 
or mixed with inhibitors (1) were incubated with 3H-labeled elastin 
for 24 h at 378C. The soluble radioactivity was measured by liquid 
scintillation spectroscopy as counts per minute per microgram pro-
tein. The selective inhibitors E64 (20 mM), or EDTA (20 mM) were 
used to determine degree of elastin degradation by cysteine pro-
teases, and MMPs, respectively.Regional Expression of Elastolytic Cathepsins S and K in Human Atheroma 581
Discussion
Recent clinical and pathological findings have identified rup-
ture of the fibrous cap of human atherosclerotic plaques as a
major mechanism underlying coronary artery thrombosis (1,
25). Thus, the metabolism of the extracellular matrix compo-
nents collagen and elastin, which confer structural integrity
upon the lesion’s fibrous cap, can critically influence the clini-
cal manifestations of atherosclerosis. We and others have
therefore studied regulation of the integrity of the arterial ex-
tracellular matrix. Abundant evidence now supports a poten-
tial role for MMPs in this context (4, 5, 26, 27).
This report demonstrates by immunostaining that cells
that migrate into and accumulate within developing intimal
plaques also synthesize the potent elastases, cathepsins K and
S. These studies do not demonstrate secretion of active cathep-
sins K and S in situ, as there is no available signature for activi-
ties of these enzymes in vivo at present. However, we have ver-
ified that cytokine-stimulated vascular SMC can use cathepsin
S to degrade extracellular, insoluble elastin in vitro (Fig. 8).
Expression of this SMC elastolytic potential required activa-
tion by certain cytokines such as IFN-g and IL-1b, found in de-
veloping plaques (28–30). In cultured rabbit articular chondro-
cytes (31), IL-1b increased production but not secretion of
cathepsin B, and both IL-1b and TNF-a stimulated the secre-
tion of a latent cysteine proteinase activity from human syno-
vial fibroblast-like cells (32). Cells within atheroma frequently
display markers of exposure to IFN-g such as MHC class II
molecules (33), consistent with our observation of expression
of cathepsin S by lesional cells and our hypothesis that SMCs
in developing plaques can utilize these enzymes in matrix re-
modeling.
In contrast with prior studies of elastase activities of vascu-
lar SMC, which utilized cell lysates (7, 8), we have examined
the elastolytic potential of living SMC. Unstimulated SMC dis-
played little or no elastolytic activity but, in response to cyto-
kine stimulation, degraded particulate elastin in a manner sim-
ilar to that of human monocyte-derived macrophages, which
also largely utilized cathepsins S and L for elastolysis (12). At
least in vitro, SMC elastolytic activity was z 10-fold less than
that of stimulated macrophages (12). The capacity of stimu-
lated SMC, like macrophages, to use these enzymes in extra-
cellular matrix remodeling resembles the physiological behav-
ior of osteoclasts (13, 34). Previous reports of accumulation of
the bone matrix protein osteopontin in atheroma, and os-
teopontin expression by SMC after vascular wall injury, agree
with concept of “activation” of SMC at sites of vessel wall re-
modeling and atherogenesis (35). Although the SMC used in
Figure 6. Cytokines stimulate cathepsin S production in cultured 
SMC. Unstimulated SMC (top) contain no immunoreactive cathepsin 
S, whereas those stimulated for 24 h with IL-1b (10 ng/ml, middle) 
show substantial staining for this enzyme. The bottom panel shows a 
control with pre-immune serum. 3400.
Figure 7. Northern blots of total RNA from vascular SMC cultured 
under different conditions. 30 mg of total RNA harvested from cells 
treated as noted were separated on 1.2% agarose gel and blotted onto 
a nylon filter. The filter was hybridized with both a-[32P]dCTP-
labeled cDNA probes for cathepsin S and cathepsin K, and exposed 
to X-Omat film (Eastman Kodak) at 2808C.582 Sukhova et al.
our in vitro studies appear to express and secrete predomi-
nantly cathepsin S to degrade particulate elastin (Fig. 8), our
immunostaining showed substantial immunoreactivity of ca-
thepsin K in both SMC and macrophages within atheroma
(Figs. 1 and 2). In the complex environment of the atheroma
cathepsin K and potentially other elastolytic cathepsins such as
cathepsin L (12) may contribute along with cathepsin S to vas-
cular wall remodeling.
The increase in elastolytic activity observed in atheromata,
as compared with normal tissue (Fig. 4), was almost entirely
due to papain-type cysteine proteases. This observation corre-
lates well with our findings that atheroma contain large clus-
ters of cathepsin K- and S-positive macrophages and SMC. Im-
munostaining and Western blot analyses disclosed little or no
expression of these enzymes in the uninvolved arterial tissue.
It is noteworthy that neither cathepsins nor metalloproteinases
appear to account for all of the measured elastase activities.
This residual activity, although not different between normal
and diseased arteries, remains unexplained. Some or all of this
activity could be due to serine proteases, which have previ-
ously been isolated from similar extracts of vessel walls and
shown to contribute to elastase(s) in such extracts (7, 8).
The localization of cathepsin K in SMC and macrophages
within atheroma establishes a novel source of this enzyme ex-
pression outside of bone. Analysis of the promoter region of
cathepsin K reveals hallmarks of a weakly regulated gene at
the transcriptional level, a conclusion supported by prior work
demonstrating low constitutive levels of cathepsin K mRNA in
numerous tissues (34, 36). However, cathepsin K protein was
not observed in numerous normal tissues examined and it has
been considered to be selectively expressed in bone. In con-
trast, as judged both by immunostaining and immunoblotting
of whole tissue extracts, our data show the presence of cathep-
sin K protein within human atheroma. This finding implies
that regulation of cathepsin K expression is likely posttran-
scriptional. The lack of cathepsin K protein in unstimulated
cultured SMC, in spite of clear presence of its mRNA, sup-
ports this view.
Unlike cathepsin K, the levels of both cathepsin S mRNA
and protein strongly increased in primary cultures of vascular
SMC exposed to either IFN-g or IL-1b. This response to cy-
tokines is consistent with the highly regulated nature of the
cathepsin S promoter (16, 21), and the response to IFN-g con-
sistent with prior proposals that cathepsin S may contribute to
processing of antigen for MHC class II molecules (33). The re-
sponse to IL-1b in vitro has potential in vivo relevance as im-
munoreactive cathepsin S and IL-1b colocalize in macro-
phage-derived foam cells within atheroma (data not shown).
The findings that atheroma contain abundant elastolytic
cathepsins have potential therapeutic interest. These enzymes
localize to sites of plaques prone to rupture and these cathep-
sins can mediate extensive matrix breakdown. The present ob-
servations suggest that even effective inhibition of MMP may
not suffice to arrest enzymatic breakdown of the arterial extra-
cellular matrix, and identify elastolytic cathepsins as an addi-
tional potential therapeutic target in this setting.
Acknowledgments
We thank our colleagues Dr. M.W. Muszcynski for providing cul-
tured cells for this study and E. Shvartz for technical assistance.
Grants from the National Heart, Lung, and Blood Institute to P.
Libby (HL-34636), H. Chapman (HL-48261), and D. Simon (HL/DK-
57506) supported this work. D.I. Simon is the recipient of grant-in-aid
#13-526-945 from the American Heart Association, Massachusetts af-
filiate. G.-P. Shi is the recipient of a Scientist Development Grant
(#9730157N) from the American Heart Association.
References
1. Davies, M.J. 1996. Stability and instability: two faces of coronary athero-
sclerosis. The Paul Dudley White lecture, 1995. Circulation. 94:2013–2020.
Figure 8. SMC secrete an active cysteine protease that can degrade 
extracellular elastin. (A) Elastin degradation by cultured human vas-
cular SMC in the presence (black bars) or absence (white bars) of 
IFN-g and various protease inhibitors as indicated in the figure. The 
relative amounts of elastin degradation are presented as micrograms 
of elastin degraded (mean6SD) per million cells in 24 h (mean6SD) 
from four independent experiments. (B) IFN-g stimulates cultured 
SMC to express and secrete active cathepsin S. Cell lysates and pro-
tein precipitated from culture media were electrophoresed and im-
munoblotted for cathepsin S (left). Recombinant cathepsin S (S) 
marks the migration position of active enzyme. The higher molecular 
weight species present in the lysates of IFN-g-stimulated cells are 
consistent with the known precursor forms of cathepsin S (11). Active 
cysteine proteases were present in both cell lysates and conditioned 
media as judged by active site labeling with [125I]tyr-ala-CHN2 (right).Regional Expression of Elastolytic Cathepsins S and K in Human Atheroma 583
2. Libby, P., and S.K. Clinton. 1993. The role of macrophages in atherogen-
esis. Curr. Op. Lipidol. 4:355–363.
3. van der Wal, A.C., A.E. Becker, C.M. van der Loos, and P.K. Das. 1994.
Site of intimal rupture or erosion of thrombosed coronary atherosclerotic
plaques is characterized by an inflammatory process irrespective of the domi-
nant plaque morphology. Circulation. 89:36–44.
4. Henney, A.M., P.R. Wakeley, M.J. Davies, K. Foster, R. Hembry, G.
Murphy, and S. Humphries. 1991. Localization of stromelysin gene expression
in atherosclerotic plaques by in situ hybridization. Proc. Natl. Acad. Sci. USA.
88:8154–8158.
5. Galis, Z.S., G.K. Sukhova, M.W. Lark, and P. Libby. 1994. Increased ex-
pression of matrix metalloproteinases and matrix-degrading activity in vulnera-
ble regions of human atherosclerotic plaques. J. Clin. Invest. 94:2493–2503.
6. Galis, Z.S., G.K. Sukhova, and P. Libby. 1995. Microscopic localization
of active proteases by in situ zymography: detection of matrix metalloprotein-
ase activity in vascular tissue. FASEB (Fed. Am. Soc. Exp. Biol.) J. 9:974–980.
7. Zhu, L., D. Wigle, A. Hinek, J. Kobayashi, C. Ye, M. Zuker, H. Dodo,
F.W. Keeley, and M. Rabinovitch. 1994. The endogenous vascular elastase that
governs development and progression of monocrotaline-induced pulmonary
hypertension in rats is a novel enzyme related to the serine proteinase adipsin.
J. Clin. Invest. 94:1163–1171.
8. Leake, D.S., W. Hornebeck, D. Brechemier, L. Robert, and T.J. Peters.
1983. Properties and subcellular localization of elastase-like activities of arterial
smooth muscle cells in culture. Biochim. Biophys. Acta. 761:41–47.
9. Shapiro, S.D., E.J. Campbell, H.G. Welgus, and R.M. Senior. 1990. Elas-
tin degradation by mononuclear phagocytes. Ann. NY Acad. Sci. 318:747–752.
10. Xin, X.-Q., B. Gunesekera, and R.W. Mason. 1992. The specificity and
elastinolytic activities of bovine cathepsins S and H. Arch. Biochem. Biophys.
299:334–339.
11. Shi, G.-P., J.S. Munger, J.P. Meara, D.H. Rich, and H.A. Chapman.
1992. Molecular cloning and expression of human alveolar macrophage cathep-
sin S, an elastinolytic cysteine protease. J. Biol. Chem. 267:7258–7262.
12. Reddy, V.Y., Q.-Y. Zhang, and S.J. Weiss. 1995. Pericellular mobiliza-
tion of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by hu-
man monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA. 92:3849–
3853.
13. Bossard, M.J., T.A. Tomaszek, S.K. Thompson, B.Y. Amegadzie, C.R.
Hanning, C. Jones, J.T. Kurdyla, D.E. McNulty, F.H. Drake, M. Gowen, and
M.A. Levy. 1996. Proteolytic activity of human osteoclast cathepsin K. Expres-
sion, purification, activation, and substrate identification. J. Biol. Chem. 271:
12517–12524.
14. Bromme, D., K. Okamoto, B.B. Wang, and S. Biros. 1996. Human
cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteo-
clasts. J. Biol. Chem. 271:2126–2132.
15. Kafienah, W., D. Bromme, D.J. Buttle, L.J. Croucher, and A.P. Hol-
lander. 1998. Human cathepsin K cleaves native type I and II collagens at the
N-terminal end of the triple helix. Biochem. J. 331:727–732.
16. Petanceska, S., and L. Devi. 1992. Sequence analysis, tissue distribution,
and expression of rat cathepsin S. J. Biol. Chem. 267:26038–26043.
17. Bromme, D., P.R. Bonneau, P. Lachance, B. Wiederanders, H. Kirschke,
C. Peters, D.Y. Thomas, A.C. Storer, and T. Vernet. 1993. Functional expres-
sion of human cathepsin S in Saccharomyces cerevisiae. Purification and char-
acterization of the recombinant enzyme. J. Biol. Chem. 268:4832–4838.
18. Rankin, S.M., M.E. Knowles, and D.S. Leake. 1989. Macrophages pos-
sess both neutral and acidic protease activities toward low density lipoproteins.
Atherosclerosis. 79:71–78.
19. Gelb, B.D., G.-P. Shi, H.A. Chapman, and R.J. Desnick. 1996. Pycnody-
sostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 273:
1236–1238.
20. Littlewood-Evans, A.J., G. Bilbe, W.B. Bowler, D. Farley, B. Wlodar-
ski, T. Kokubo, T. Inaoka, J. Sloane, D.B. Evans, and J.A. Gallagher. 1997. The
osteoclast-associated protease cathepsin K is expressed in human breast carci-
noma. Cancer Res. 57:5386–5390.
21. Shi, G.-P., A.C. Webb, K.E. Foster, J.H.M. Knoll, C.A. Lemere, J.S.
Munger, and H.A. Chapman. 1994. Human cathepsin S: chromosomal localiza-
tion, gene structure, and tissue distribution. J. Biol. Chem. 369:11530–11536.
22. Shi, G.-P., H.A. Chapman, S.M. Bhairi, C. DeLeeuw, V.Y. Reddy, and
S.J. Weiss. 1995. Molecular cloning of human cathepsin O, a novel endoprotein-
ase and homologue of rabbit OC2. FEBS (Fed. Eur. Biochem. Soc.) Lett. 357:
129–134.
23. Munger, J.S., G.-P. Shi, E.A. Mark, D.T. Chin, C. Gerard, and H.A.
Chapman. 1991. A serine esterase released by human alveolar macrophages is
closely related to liver microsomal carboxylesterases. J. Biol. Chem. 266:18832–
18838.
24. Banda, M.J., Z. Werb, and J.H. McKerrow. 1987. Elastin degradation.
Methods Enzymol. 144:288–305.
25. Libby, P., and K.V. O’Brien. 1983. Culture of quiescent arterial smooth
muscle cells in a defined serum-free medium. J. Cell. Physiol. 115:217–223.
26. Falk, E., P.K. Shah, and V. Fuster. 1995. Coronary plaque disruption.
Circulation. 92:657–671.
27. Werb, Z., D.F. Bainton, and P.A. Jones. 1980. Degradation of connec-
tive tissue matrices by macrophages. J. Exp. Med. 152:1537–1553.
28. Libby, P., J.M. Ordovas, L.K. Birinyi, K.R. Auger, and C.A. Dinarello.
1986. Inducible interleukin-1 expression in human vascular smooth muscle
cells.  J. Clin. Invest. 78:1432–1438.
29. Clinton, S.K., J.C. Fleet, H. Loppnow, R.N. Salomon, B.D. Clark, J.G.
Cannon, A.R. Shaw, C.A. Donarello, and P. Libby. 1991. Interleukin-1 gene ex-
pression in rabbit vascular tissue in vivo. Am. J. Pathol. 138:1005–1014.
30. Libby, P. 1996. Vascular cells produce and respond to cytokines. In Im-
mune Functions of the Vessel Wall. G. Hansson and P. Libby, editors. Har-
wood Academic Publishers, New York. 45–64.
31. Baici, A., and A. Lang. 1990. Effect of interleukin-1b on the production
of cathepsin B by rabbit articular chondrocytes. FEBS (Fed. Eur. Biochem.
Soc.) Lett. 277:93–96.
32. Huet, G., R.-M. Flipo, C. Colin, A. Janin, B. Hemon, M. Collyn-
D’Hooghe, R. Lafyatis, B. Duquesnoy, and P. Degand. 1993. Stimulation of the
secretion of latent cysteine proteinase activity by tumor necrosis factor a and
interleukin-1. Arthritis Rheum. 36:772–779.
33. Riese, R.J., P.R. Wolf, D. Bromme, L.N. Natkin, J.A. Villadangos, H.L.
Ploegh, and H.A. Chapman. 1996. Essential role for cathepsin S in MHC class
II-associated invariant chain processing and peptide loading. Immunity. 4:357–
366.
34. Drake, F.H., R.A. Dodds, I.E. James, J.R. Connor, C. Debouck, S. Rich-
ardson, E. Lee-Rykaczewski, L. Coleman, D. Rieman, R. Barthlow, G. Has-
tings, and M. Gowen. 1996. Cathepsin K, but not cathepsins B, L, or S, is abun-
dantly expressed in human osteoclasts. J. Biol. Chem. 271:12511–12516.
35. Yamamoto, M., M. Aoyagi, H. Azuma, and K. Yamamoto. 1997.
Changes in osteopontin mRNA expression during phenotypic transition of rab-
bit arterial smooth muscle cells. Histochem. Cell Biol. 107:279–287.
36. Gelb, B.D., G.-P. Shi, M. Heller, S. Weremowicz, C. Morton, R.J.
Desnick, and H.A. Chapman. 1997. Structure and chromosomal assignment of
the human cathepsin K gene. Genomics. 41:267–277.